The Glucagon Emergency Kit is an FDA-approved and cost-effective alternative to treat severe hypoglycemic episodes in people with diabetes.
This kit includes Glucagon for Injection 1 mg and a prefilled glass syringe with 1 mL of Sterile Water for Injection, USP.
The Glucagon Emergency Kit is designed to be convenient and easy to use. Patients can carry it with them, so it is available should they experience severe hypoglycemia.
The bright orange case makes it easy for a patient or caregiver to find it and act quickly. To help make the Glucagon Emergency Kit more affordable, there is a co-pay assistance programme for patients who qualify.
Fresenius Kabi is also making injection training kits available to health care providers to help educate patients.
Glucagon for Injection is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients.
The company's US headquarters is in Lake Zurich, Illinois. The company's global headquarters is in Bad Homburg, Germany.
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
MaaT Pharma receives negative CHMP trend vote for MaaT013
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products